ADCs

With over ten years of experience supporting antibody drug conjugate (ADC) discovery, development and manufacturing, our multidisciplinary team has worked with a range of different antibodies, linkers and toxins to enable us to develop customised bioconjugation approaches and offer complex ADC solutions to our customers.

All articles

Scientist in the lab

Article7 min read

ADC Overview Read more

Image taken from antibody drug conjugates ADCs at Sterling animation

Animation2 min read

Antibody drug conjugates (ADCs) at Sterling Read more

News2 min read

Sterling expands ADC capabilities and laboratory capacity at Deeside

Sterling Pharma Solutions today announced a £1 million expansion project at its Deeside, UK site, which is the company’s dedicated bioconjugation and antibody-drug conjugates (ADCs) facility. The project will increase the current laboratory space from 275 to 419 square meters and establish cGMP bioconjugation/ADC manufacturing capabilities.

Read more

One pager2 min read

Native intact analysis of a cysteine linked antibody drug conjugate

Native intact analysis of Brentuximab Vedotin using a SCIEX X500B Mass Spectrometer

Read more

One pager2 min read

Intact mass analysis of a therapeutic monoclonal antibody biosimilar Read more

One pager2 min read

Reduced subunit analysis of a cysteine linked antibody drug conjugate Read more

One pager2 min read

Reduced subunit analysis of a therapeutic monoclonal antibody Read more

One pager2 min read

Intact mass analysis of a therapeutic lysine linked antibody drug conjugate

DAR of Trastuzumab Emtansine (Kadcyla) using a SCIEX X500B Mass Spectrometer

Read more

One pager2 min read

Peptide digestion analysis of a monoclonal therapeutic antibody Read more

Next Page »

Explore more

All ADCs API Development API Manufacturing Analytical Services Drug Discovery Facilities News PDMO People Peptides Sustainability Technologies

Sign up for updates

Be the first to see the latest articles and updates from industry leaders, delivered straight to your inbox

Phone

This field is for validation purposes and should be left unchanged.

Name(Required)

Email(Required)

Company Name(Required)

This field is hidden when viewing the form

Prospect Source

Please click here for our privacy policy

Service. Passion. Science.

PDMO^® is registered in the U.S. Patent and Trademark Office.

PDMO^® is a registered trademark of Sterling Pharma Solutions Limited (EUIPO and UKIPO). All rights reserved.

Sterling Pharma Solutions Limited. Registration number: 05712796. Registered office address: Dudley Lane, Dudley, Cramlington, NE23 7QG, United Kingdom. Registered in England.
VAT number: GB320549229